Vaccinations in respiratory medicine

HNO
H M Lode, R Stahlmann

Abstract

Vaccinations are the most successful and cost-effective measures for prevention of infections. Important pathogens of respiratory tract infections (e.g. influenza viruses and pneumococci) can be effectively treated by vaccinations. The seasonal trivalent and recently now quadrivalent influenza vaccines include antigens from influenza A and B type viruses, which have to be modified annually oriented to the circulating strains. The effective protection by influenza vaccination varies considerably (too short protection time, mismatch); therefore, administration late in the year is the best approach (November/December). Two pneumococcal vaccines are recommended for adults: the over 30-year-old 23-valent polysaccharide vaccine (PPV23) and the 4-year-old 13-valent conjugate vaccine (PCV13). The immunological and clinical efficacy of PPV23 is controversially discussed; however, a moderate reduction of invasive pneumococcal infections is widely accepted. The PCV13 stimulates a T-cell response and has currently demonstrated its clinical efficacy in an impressive study (CAPiTA). The problem of PCV13 is the relatively limited coverage of only 47% of the currently circulating invasive pneumococcal serotypes.

References

Jun 3, 2005·The New England Journal of Medicine·M N OxmanUNKNOWN Shingles Prevention Study Group
Feb 25, 2006·Cell·Shizuo AkiraOsamu Takeuchi
Mar 30, 2007·The New England Journal of Medicine·David W Kimberlin, Richard J Whitley
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrés de RouxH M Lode
Apr 16, 2009·Deutsche medizinische Wochenschrift·A H Dalpke
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Nov 2, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M WoodheadUNKNOWN Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases
Oct 29, 2011·The Lancet Infectious Diseases·Michael T OsterholmEdward A Belongia
Mar 30, 2012·The Journal of Infectious Diseases·Elizabeth A ClutterbuckAndrew J Pollard
Sep 4, 2012·American Journal of Epidemiology·Salvatore ManninoKenneth J Rothman
Jan 18, 2013·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Jan 19, 2013·Annual Review of Medicine·Natalie Pica, Peter Palese
Feb 13, 2013·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·R G PebodyJ M Watson
May 25, 2013·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·C Poethko-Müller, R Schmitz
Aug 13, 2013·Deutsche medizinische Wochenschrift·M W Pletz
Oct 23, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P DurandoT Welte
Jun 11, 2014·Deutsche medizinische Wochenschrift·M Imöhl, M van der Linden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.